Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
semaxanib · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| fluorouracil | DRUG | - |
| leucovorin calcium | DRUG | - |
| semaxanib | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed or recurrent, metastatic colorectal cancer Primary disease was adenocarcinoma of the colon or rectum Bidimensionally measurable or evaluable disease No CNS metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECO...
Top 20 of 80 competitors
Semaxanib was studied in oncology for the treatment of colorectal cancer and sarcoma. It was evaluated in metastatic colorectal cancer and in AIDS-related Kaposi's sarcoma. Semaxanib is an investigational agent and is not described as approved for any indication.
Semaxanib targets FLT1, FLT4, KDR, and KIT. It is a small molecule inhibitor of these receptor tyrosine kinases. FLT1, FLT4, and KDR are vascular endothelial growth factor receptors, and KIT is a receptor tyrosine kinase involved in certain cancers.
Semaxanib is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company associated with the clinical development of semaxanib in colorectal cancer and sarcoma.
Semaxanib has been studied in Phase 3 and Phase 1 clinical trials. The Phase 3 trial was in metastatic colorectal cancer, and the Phase 1 trial was in AIDS-related Kaposi's sarcoma. Semaxanib is investigational and is not described as FDA approved.
Semaxanib has been evaluated in two completed clinical trials. NCT00004252 was a Phase 3 study of leucovorin and fluorouracil with or without SU5416 in metastatic colorectal cancer. NCT00003720 was a Phase 1 study of SU5416 in AIDS-related Kaposi's sarcoma.
Yes, semaxanib is also known as SU5416. The clinical trial records for semaxanib use the name SU5416, including NCT00004252 in metastatic colorectal cancer and NCT00003720 in AIDS-related Kaposi's sarcoma.